Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in severe chronic rhinosinusitis with nasal polyposis
NCT04851964Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2021
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyposis (CRSwNP) comparing Tezepelumab with Placebo (2 arms). Primary endpoints: Total Nasal Polyp Score at 52 weeks and Nasal Congestion Score at 52 weeks. Started Apr 2021; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyposis (CRSwNP)
Beyond the preview
Go deeper on NCT04851964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851964.